Notes from UKHSA seasonal influenza guidelines 2021-22

• all children aged 2 to 15 (but not 16 years or older) on 31 August 2021

• those aged 6 months to under 50 years in clinical risk groups

• pregnant women

• those aged 50 years and over

• those in long-stay residential care homes

• carers

• close contacts of immunocompromised individuals

• frontline health and social care staff employed by:
  1. a registered residential care or nursing home,
  2. registered domiciliary care provider,
  3. a voluntary managed hospice provider,
  4. Direct Payment (personal budgets) and/or Personal Health Budgets, such as Personal Assistants.

One page summary

For those aged 65 years and over

• The adjuvanted quadrivalent influenza vaccine (aQIV), with

• the cell-based quadrivalent influenza vaccine (QIVc) or

• the recombinant quadrivalent influenza vaccine (QIVr) offered if aQIV is unavailable

For under-65s (including those at risk, pregnant women and 50 to 64-year-old cohort)

• QIVc or QIVr, as an alternative

• if these are not available, the egg-grown quadrivalent influenza vaccine (QIVe) should be considered for use

Children aged 2 years and over

• The live attenuated influenza vaccine (LAIV),

• QIVc, for children in at-risk groups who are contraindicated to receive LAIV. or, for children aged 2 and over whose parents object to LAIV on the ground of its porcine gelatine content.

Children in clinical risk groups aged 6 months to less than 2 years

• QIVe.

https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan/national-flu-immunisation-programme-2021-to-2022-letter

The national influenza immunisation programme 2021 to 2022